A blood product derived from human plasma that is used to augment the effects of clotting factors given to patients with hemophilia. Patients with hemophilia who have received repeated injections of clotting factors may develop antibodies to those factors, decreasing the effectiveness of hemophilia treatments. Anti-inhibitors are used to counteract the effect of the unwanted antibodies.